Novo Nordisk reports 25% average weight loss in women using experimental CagriSema drug
Novo Nordisk announced that its next‑generation obesity injection CagriSema produced an average 25% weight loss after 68 weeks in a late‑stage analysis of roughly 2,300 women with obesity or overweight. A second analysis of about 1,900 women showed weight loss of 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal participants, versus roughly 2% with placebo. The company plans to launch the drug early next year, with some outlets noting a 2027 launch timeline. Analysts project $11.84 billion in obesity‑drug sales for CagriSema in 2028.
Why it matters
FactSet consensus estimates that CagriSema could generate $11.84 billion in sales in 2028, indicating a major new revenue stream for Novo Nordisk. The announcement lifted Novo Nordisk’s share price about 2% on the day of the release.
Key facts
- 1CagriSema caused an average 25% weight loss after 68 weeks in an analysis of roughly 2,300 women with obesity or overweight. cnbc.com
- 2In the same analysis, the placebo group lost about 3% weight. cnbc.com
- 3A second analysis of around 1,900 women showed weight loss of 26.7% (premenopausal), 24.8% (perimenopausal) and 23.1% (postmenopausal) after 68 weeks. cnbc.com
- 4The placebo groups in the menopause‑stratified analysis lost approximately 2% across the three groups. cnbc.com
- 5Novo Nordisk plans to launch CagriSema early next year. cnbc.com
- 6Analysts expect CagriSema to generate $11.84 billion in obesity sales in 2028, according to a FactSet consensus estimate. cnbc.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.